Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2003-4-4
pubmed:abstractText
Albuminuria and hypertension are predictors of poor renal and cardiovascular outcome in diabetic patients. We tested whether dual blockade of the renin-angiotensin system (RAS) with both an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin II receptor blocker (ARB) is superior to maximal recommended dose of ACE inhibitor in type 1 diabetic patients with diabetic nephropathy (DN).
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0085-2538
pubmed:author
pubmed:issnType
Print
pubmed:volume
63
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1874-80
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:12675866-Adult, pubmed-meshheading:12675866-Albuminuria, pubmed-meshheading:12675866-Angiotensin-Converting Enzyme Inhibitors, pubmed-meshheading:12675866-Antihypertensive Agents, pubmed-meshheading:12675866-Biphenyl Compounds, pubmed-meshheading:12675866-Blood Pressure, pubmed-meshheading:12675866-Cross-Over Studies, pubmed-meshheading:12675866-Diabetes Mellitus, Type 1, pubmed-meshheading:12675866-Diabetic Nephropathies, pubmed-meshheading:12675866-Double-Blind Method, pubmed-meshheading:12675866-Drug Synergism, pubmed-meshheading:12675866-Drug Therapy, Combination, pubmed-meshheading:12675866-Enalapril, pubmed-meshheading:12675866-Female, pubmed-meshheading:12675866-Humans, pubmed-meshheading:12675866-Male, pubmed-meshheading:12675866-Middle Aged, pubmed-meshheading:12675866-Renin-Angiotensin System, pubmed-meshheading:12675866-Tetrazoles
pubmed:year
2003
pubmed:articleTitle
Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
pubmed:affiliation
Steno Diabetes Center, Gentofte, Denmark. pkjacobsen@dadlnet.dk
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't